39 results about "Carotenoid composition" patented technology

Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising β-carotene, γ-carotene, and δ-carotene, a phytosterol, a tocopheral and a phospholipid. Use of multi-carotenoids compositions for the treatment of urinary tract malfunctions including benign prostate hyperplasia and lower urinary tract symptoms.

The invention relates to a preparation method for stable water soluble carotenoid dry powder, the organic solvent of acetone or isopropanol dissolved with carotenoid component is added into an aqueous phase solvent containing a surfactant and adjuvant-stabilization component to be sufficiently mixed under sufficient stirring, then the organic solvent in the mixed solvent is removed and an auxiliary forming accessory which is one to twelve times of the carotenoid component by mass is added to be evenly stirred and treated with sponging frying to obtain the powder product. The preparation method is simple and easy, complex operation such as high pressure homogenization is not needed, and the procedures are less, therefore, the method is applicable to various carotenoid components containing Beta-carotene, astaxanthin, lutein, corn pigment and lycopene, etc. The method has the advantages that the performance of the products is good, the grain diameter of the powder product can be in the range of 90 to 170 nm, and the product can be evenly dispersed in water and form a stable and transparent carotenoid water dispersoid solvent.

The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.

A marigold plant, a regenerable portion thereof and seed are disclosed whose flower petals, leaves or flower petals and leaves contain one or more of an enhanced neoxanthin plus violaxanthin ratio, an enhanced β-carotene ratio, an enhanced lycopene ratio, an enhanced α-cryptoxanthin ratio, an enhanced phytoene ratio or an enhanced phytofluene ratio relative to that ratio in a non-mutant marigold. A marigold plant, a regenerable portion thereof and seed are also disclosed whose flower petals contain zeaxanthin esters and are substantially free of esters of both neoxanthin and violaxanthin, and wherein zeaxanthin constitutes at least about one-half of the extractable carotenoids when xanthophylls are assayed as alcohols. Also disclosed are methods of preparing such plants, oleoresins and comestible materials that have such carotenoid ratios.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S,S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and / or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

The present invention relates to a method in the field of shellfish breeding techniques, for breeding a scallop population that have improved carotenoid content in the orange-red adductor muscles or other muscle tissues. This method includes the steps of selecting the rare individuals that have orange-red adductor muscles from natural scallop populations, growing the selected scallops, inducing the reproduction, artificially fertilization, and finally breeding a scallop population with orange-red adductor muscles which can be expanded for the cultivation on a large scale. Comparing to other known breeding methods, the present method does not use transgenic technologies to include introduce any exogenous genes, thus does not have any bio-safety and ethics issues. All the mutant scallops with orange-red adductor muscles are selected from natural or cultivated populations. After breeding for four generations, the obtained scallops have abundant carotenoid ingredients in their orange-red adductor muscles. The obtained scallop population is genetically stable and has high survival rate, and it thus can be used for cultivation on a large scale. In summary, this breeding method is simple, low cost and the breeding scallop population has high economic and nutritious values.

The present invention relates to use of carotenoid preparations for promoting skin whitening. Particularly, the present invention discloses that a combination of phytoene and phytofluene is effective in whitening skin. The present invention further relates to carotenoid compositions comprising a combination of phytofluene and phytofluene effective in whitening skin and at least one additional carotenoid, particularly carotenoids devoid of highly intense color.